Immunocore (ADR) (IMCR)
Develops ImmTAX-based immunotherapies and sells KIMMTRAK for eligible uveal melanoma patients.
Something off on this page? Send us feedback.
Develops soluble T-cell-receptor bispecific immunotherapies through ImmTAX. KIMMTRAK is the first approved product and the only currently significant therapy-sales revenue stream; the pipeline spans cancer, infectious disease, and autoimmune disease.
Develops soluble T-cell-receptor bispecific immunotherapies using its ImmTAX platform. KIMMTRAK, its first approved product, treats HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma and supplies the company’s only currently significant therapy-sales revenue stream. It was the first TCR therapeutic to receive FDA regulatory approval.
The same platform supports programs in cancer, infectious disease, and autoimmune disease, all managed in one immunotherapies operating segment. KIMMTRAK has approvals and commercial launches across multiple countries. Operations are based primarily in the United Kingdom and United States. The commercial business depends on KIMMTRAK and on treating the defined HLA-A*02:01-positive patient population.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 7, 2026 | Morgan Stanley | Target | Target: $36 | Target: $43 |
| Aug 3, 2026 | Mizuho Securities | Target | Target: $38 | Target: $35 |
| Mar 16, 2026 | Jefferies | Downgrade | ||
| Feb 19, 2026 | Mizuho Securities | Target | Target: $72 | Target: $38 |
| Jan 7, 2026 | UBS | Target | Target: $24 | Target: $55 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $880.2M · Total debt $435.0M · Total assets $1.12B · Shareholders' equity $419.8M
- Revenue
- $115.9M
- Operating income
- −$3.0M
- Net income
- −$808.0K
No dividends on record.
| Institutions | 101.18% | 52.11M ADS | |
|---|---|---|---|
| 145 holders · as of Jun 30, 2026 | |||
| Insiders | 17.94% | 9.24M ADS | |
| 6 holders · as of Feb 19, 2026 | |||
| Strategic holders | 8.61% | 4.43M ADS | |
| 2 holders · as of Mar 19, 2025 | |||
| Adds to | 127.73% | ||
51.50M ADS as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 127.73%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Wellington Management Group LLPInstitution | 11.11% | 5.72M ADS | as of Jun 30, 2026 |
RTW Investments, LPInstitution | 9.46% | 4.87M ADS | as of Jun 30, 2026 |
Bahija Jallal1Insiderdirector, officer: CHIEF EXECUTIVE OFFICER | 8.75% | 4.49M ordinary | filed Feb 19, 2026 |
FMR LLCInstitution | 8.36% | 4.31M ADS | as of Jun 30, 2026 |
Primecap Management Co/CA/Institution | 7.06% | 3.64M ADS | as of Jun 30, 2026 |
- Bahija Jallal's transaction reports restate only vehicles that traded; the 2025 ownership statement (4.49M) plus the 12.3K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Feb 18, 2026 | David M. Berman | officer: HEAD OF R&D | −5,965 | $32.35 |
| Feb 18, 2026 | Tina Amber st Leger | officer: CHIEF HR OFFICER | −1,000 | $32.35 |
| Feb 18, 2026 | John Goll | officer: SVP, FINANCE & CAO | −698 | $32.35 |
| Feb 18, 2026 | Bahija Jallal | director, officer: CHIEF EXECUTIVE OFFICER | −11,474 | $32.35 |
| Dec 4, 2025 | David M. Berman | officer: HEAD OF R&D | −31,341 | $40.26 |
- IDEAYA Biosciences
Darovasertib advances across primary and metastatic uveal melanoma
- Immatics
PRAME TCR therapies in metastatic uveal melanoma and solid tumors
- Replimune Group
Oncolytic-virus and PD-1 regimen in metastatic uveal melanoma
- Bristol-Myers Squibb
Checkpoint-inhibitor regimen evaluated in metastatic uveal melanoma
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Immunocore (ADR) | $31.13 | −3.98% | $1.65B | — | — | 4.1 | −13.7% |
| IDEAYA Biosciences | $37.91 | −4.55% | $3.78B | — | — | 16.1 | — |
| Immatics | $8.64 | −2.59% | $1.19B | — | — | 25.0 | +113.0% |
| Replimune Group | $12.74 | −5.42% | $1.13B | — | — | — | — |
| Bristol-Myers Squibb | $61.74 | −0.82% | $127.16B | 13.7 | 9.7 | 2.6 | +5.7% |
| Median | 13.7 | 9.7 | 16.1 | +59.3% |